![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Alberta Cancer Board |
---|---|
Information provided by: | Alberta Cancer Board |
ClinicalTrials.gov Identifier: | NCT00530569 |
About 30% of breast cancers have higher than normal levels of a cellular marker called HER2. The amount of HER2 is often measured in breast tissue. A higher level of this marker usually indicates a more aggressive type of breast cancer. Cytokeratin is a second cellular marker found in breast cancer cells. Detection of Circulating cytokeratin in the blood could indicate the presence of cancer. The Pathology Department of the Tom Baker Cancer Center is doing this study to see if measuring the levels of circulating HER2 and cytokeratin, through blood testing has clinical significance for patients with breast cancer.
Condition | Intervention |
---|---|
Breast Cancer |
Procedure: Blood Test |
Study Type: | Observational |
Study Design: | Screening, Cross-Sectional, Defined Population, Prospective Study |
Official Title: | Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy |
Estimated Enrollment: | 60 |
Study Start Date: | August 2007 |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Anthony M. Magliocco, M.D. | 403-521-3165 | tonymagl@cancerboard.ab.ca |
Contact: Leanne Deman | 403-521-3769 | leannede@cancerboard.ab.ca |
Canada, Alberta | |
Tom Baker Cancer Centre | Recruiting |
Calgary, Alberta, Canada, T2N 4N2 | |
Principal Investigator: Anthony M Magliocco, M.D. |
Principal Investigator: | Anthony M Magliocco, M.D. | Alberta Cancer Board |
Study ID Numbers: | 17924 |
Study First Received: | September 13, 2007 |
Last Updated: | September 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00530569 |
Health Authority: | Canada: Ethics Review Committee |
Breast Cancer Herceptin Therapy |
Skin Diseases Trastuzumab Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |